TABLE 1.
Clinical and phenotypic characteristics of the study population
| HCs | Patients | ||||
|---|---|---|---|---|---|
| Total | Asthma | Asthma+CRSwNP | N-ERD | ||
| Subjects (n) | 100 | 103 | 54 | 29 | 20 |
| Age (years) | 59.1 ±18.0 | 44.2±19.7* | 36.9±18.7* | 49.5±18.9*,# | 56.6±14.9# |
| Female sex | 65.7 | 59.2 | 57.4 | 58.6 | 65.0 |
| Atopy | 0 | 70.9* | 87.0* | 58.6*,# | 45.0*,# |
| PBE (cells·µL−1) | 113.0±78.47 | 486.5±335.4* | 395.2±254.3* | 626.2±429.2*,# | 530.6±310.6* |
| Total IgE (kU·L−1) | 67.7±103.5 | 420.7±591.7* | 500.1±684.3* | 338.7±504.8* | 309.7±363.3* |
Values are expressed as mean±sd or %, unless otherwise indicated. Only statistically significant differences are indicated. HC: healthy control; CRSwNP: chronic rhinosinusitis with nasal polyposis; N-ERD: nonsteroidal anti-inflammatory drug-exacerbated respiratory disease; PBE: peripheral blood eosinophil. *: p<0.05 compared to HCs; #: p<0.05 compared to the asthma group.